GTCR to acquire ZENTIVA

GTCR has agreed to acquire ZENTIVA in a transaction announced on 19 February 2026. The deal involves the pharmaceutical sector, classified under NaceV2Sector_C_21. No financial consideration or deal value was disclosed in the available information. The transaction is currently subject to regulatory approval and has not yet been completed.

The acquisition represents a significant development for the target company within its specific industry classification. As the deal remains in the review phase, final completion depends on the outcome of regulatory assessments. No details regarding the specific consideration type or the country of the target have been reported. The parties involved have not yet confirmed the final status of the agreement beyond the current review stage. This summary reflects the limited data available regarding the structure and timing of the transaction.